Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Oncologist

Retrieve available abstracts of 56 articles:
HTML format
Text format



Single Articles


    June 2018
  1. TOI Y, Sugawara S, Kawashima Y, Aiba T, et al
    Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
    Oncologist. 2018 Jun 22. pii: theoncologist.2017-0384.
    PubMed     Text format     Abstract available


    April 2018
  2. CHABNER BA, Nabel CS
    Canakinumab and Lung Cancer: Intriguing, but Is It Real?
    Oncologist. 2018 Apr 17. pii: theoncologist.2018-0116.
    PubMed     Text format    


  3. LABABEDE O, Meziane MA
    The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0659.
    PubMed     Text format     Abstract available


  4. CHU CY, Choi J, Eaby-Sandy B, Langer CJ, et al
    Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0582.
    PubMed     Text format     Abstract available


  5. AHLUWALIA MS, Becker K, Levy BP
    Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0572.
    PubMed     Text format     Abstract available


    March 2018
  6. SAROCCHI M, Grossi F, Arboscello E, Bellodi A, et al
    Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
    Oncologist. 2018 Mar 22. pii: theoncologist.2017-0452.
    PubMed     Text format     Abstract available


  7. SUH JH, Schrock AB, Johnson A, Lipson D, et al
    Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.
    Oncologist. 2018 Mar 14. pii: theoncologist.2017-0493.
    PubMed     Text format     Abstract available


    February 2018
  8. MARRONE KA, Zhou X, Forde PM, Purtell M, et al
    A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naive Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2018 Feb 27. pii: theoncologist.2017-0465.
    PubMed     Text format     Abstract available


  9. VON PAWEL J, Spigel DR, Ervin T, Losonczy G, et al
    Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2018 Feb 7. pii: theoncologist.2017-0690.
    PubMed     Text format     Abstract available


    January 2018
  10. KHOZIN S, Abernethy AP, Nussbaum NC, Zhi J, et al
    Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Oncologist. 2018 Jan 9. pii: theoncologist.2017-0353.
    PubMed     Text format     Abstract available


    December 2017
  11. ODOGWU L, Mathieu L, Goldberg KB, Blumenthal GM, et al
    FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Oncologist. 2017 Dec 14. pii: theoncologist.2017-0425.
    PubMed     Text format     Abstract available


  12. OGAWA A, Kondo K, Takei H, Fujisawa D, et al
    Decision-Making Capacity for Chemotherapy and Associated Factors in Newly Diagnosed Patients with Lung Cancer.
    Oncologist. 2017 Dec 6. pii: theoncologist.2017-0187.
    PubMed     Text format     Abstract available


    September 2017
  13. KUDERER NM, Poniewierski MS, Culakova E, Lyman GH, et al
    Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
    Oncologist. 2017 Sep 26. pii: theoncologist.2017-0205.
    PubMed     Text format     Abstract available


    August 2017
  14. PAI-SCHERF L, Blumenthal GM, Li H, Subramaniam S, et al
    FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
    Oncologist. 2017 Aug 23. pii: theoncologist.2017-0078.
    PubMed     Text format     Abstract available


  15. STINCHCOMBE TE
    Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer.
    Oncologist. 2017 Aug 4. pii: theoncologist.2017-0204.
    PubMed     Text format     Abstract available


    July 2017
  16. HAN Y, Zhang R, Lin G, Zhang K, et al
    Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer.
    Oncologist. 2017 Jul 12. pii: theoncologist.2017-0042.
    PubMed     Text format     Abstract available


    May 2017
  17. SCILLA KA, Bentzen SM, Lam VK, Mohindra P, et al
    Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Oncologist. 2017 May 22. pii: theoncologist.2016-0443.
    PubMed     Text format     Abstract available


  18. MIYAUCHI E, Inoue A, Usui K, Sugawara S, et al
    Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Oncologist. 2017 May 19. pii: theoncologist.2017-0059.
    PubMed     Text format     Abstract available


  19. YAO ZH, Liao WY, Ho CC, Chen KY, et al
    Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Oncologist. 2017 May 15. pii: theoncologist.2016-0331.
    PubMed     Text format     Abstract available


  20. BAIK CS, Myall NJ, Wakelee HA
    Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
    Oncologist. 2017 May 9. pii: theoncologist.2016-0458.
    PubMed     Text format     Abstract available


    April 2017
  21. AGGARWAL C, Borghaei H
    Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
    Oncologist. 2017 Apr 13. pii: theoncologist.2016-0345.
    PubMed     Text format     Abstract available


  22. NISHIJIMA TF, Shachar SS, Nyrop KA, Muss HB, et al
    Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Oncologist. 2017;22:470-479.
    PubMed     Text format     Abstract available


    February 2017
  23. ROTH JA, Goulart BH, Ravelo A, Kolkey H, et al
    Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.
    Oncologist. 2017 Feb 27. pii: theoncologist.2016-0253.
    PubMed     Text format     Abstract available


  24. WANG X, Wang X, Hodgson L, George SL, et al
    Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Oncologist. 2017;22:189-198.
    PubMed     Text format     Abstract available


    January 2017
  25. DONG ZY, Zhai HR, Hou QY, Su J, et al
    Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.
    Oncologist. 2017;22:61-69.
    PubMed     Text format     Abstract available


  26. BARSANTI-INNES B, Hey SP, Kimmelman J
    The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.
    Oncologist. 2017;22:89-96.
    PubMed     Text format     Abstract available


    November 2016
  27. SOCINSKI MA, Villaruz LC, Ross J
    Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.
    Oncologist. 2016 Nov 7. pii: theoncologist.2016-0285.
    PubMed     Text format     Abstract available


  28. TOMASINI P, Walia P, Labbe C, Jao K, et al
    Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.
    Oncologist. 2016 Nov 2. pii: theoncologist.2015-0084.
    PubMed     Text format     Abstract available


    October 2016
  29. LIU J, Wu L, Wu G, Hu X, et al
    A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2016 Oct 27. pii: theoncologist.2016-0256.
    PubMed     Text format     Abstract available


    September 2016
  30. CHIAPPORI AA, Otterson GA, Dowlati A, Traynor AM, et al
    A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
    Oncologist. 2016 Sep 30. pii: theoncologist.2016-0220.
    PubMed     Text format     Abstract available


  31. WANG J, Zhou Z, Liang J, Feng Q, et al
    Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
    Oncologist. 2016 Sep 14. pii: theoncologist.2016-0155.
    PubMed     Text format     Abstract available


    August 2016
  32. HERZBERG B, Campo MJ, Gainor JF
    Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Oncologist. 2016 Aug 17. pii: theoncologist.2016-0189.
    PubMed     Text format     Abstract available


  33. O'KANE GM, Labbe C, Doherty MK, Young K, et al
    Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
    Oncologist. 2016 Aug 17. pii: theoncologist.2016-0164.
    PubMed     Text format     Abstract available


    July 2016
  34. LEVY B, Hu ZI, Cordova KN, Close S, et al
    Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
    Oncologist. 2016 Jul 7. pii: theoncologist.2016-0082.
    PubMed     Text format     Abstract available


    June 2016
  35. CAMPO M, Al-Halabi H, Khandekar M, Shaw AT, et al
    Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
    Oncologist. 2016 Jun 27. pii: theoncologist.2015-0508.
    PubMed     Text format     Abstract available


  36. HORN L, Reck M, Spigel DR
    The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
    Oncologist. 2016 Jun 27. pii: theoncologist.2015-0523.
    PubMed     Text format     Abstract available


  37. KAZANDJIAN D, Blumenthal GM, Luo L, He K, et al
    Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
    Oncologist. 2016 Jun 21. pii: theoncologist.2016-0101.
    PubMed     Text format     Abstract available


  38. EATON KD, Jagels B, Martins RG
    Value-Based Care in Lung Cancer.
    Oncologist. 2016 Jun 2. pii: theoncologist.2016-0116.
    PubMed     Text format    


    May 2016
  39. DAGOGO-JACK I, Shaw AT
    Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
    Oncologist. 2016 May 31. pii: theoncologist.2016-0179.
    PubMed     Text format    


  40. ALI SM, Hensing T, Schrock AB, Allen J, et al
    Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Oncologist. 2016 May 31. pii: theoncologist.2015-0497.
    PubMed     Text format     Abstract available


  41. SUH JH, Johnson A, Albacker L, Wang K, et al
    Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Oncologist. 2016 May 5. pii: theoncologist.2016-0030.
    PubMed     Text format     Abstract available


    April 2016
  42. CASTELLANOS EH, Horn L
    Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
    Oncologist. 2016 Apr 6. pii: theoncologist.2015-0396.
    PubMed     Text format     Abstract available


  43. OLSZANSKI AJ, Smith DC, Camacho LH, Thompson J, et al
    Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
    Oncologist. 2016;21:402-3.
    PubMed     Text format     Abstract available


    March 2016
  44. SUL J, Blumenthal GM, Jiang X, He K, et al
    U.S. Food and Drug Administration Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Oncologist. 2016 Mar 29. pii: theoncologist.2015-0498.
    PubMed     Text format     Abstract available


  45. HEIST RS, Shim HS, Gingipally S, Mino-Kenudson M, et al
    MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
    Oncologist. 2016 Mar 28. pii: theoncologist.2015-0510.
    PubMed     Text format     Abstract available


  46. KAZANDJIAN D, Suzman DL, Blumenthal G, Mushti S, et al
    FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Oncologist. 2016 Mar 16. pii: theoncologist.2015-0507.
    PubMed     Text format     Abstract available


  47. SIVA S, Ball D
    Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens.
    Oncologist. 2016 Mar 16. pii: theoncologist.2015-0477.
    PubMed     Text format    


  48. CIARDIELLO F, Adams R, Tabernero J, Seufferlein T, et al
    Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.
    Oncologist. 2016;21:292-300.
    PubMed     Text format     Abstract available


    February 2016
  49. DE LA TORRE-VALLEJO M, Turcott J, Arrieta O, Baracos V, et al
    In Reply.
    Oncologist. 2016;21:e2.
    PubMed     Text format    


  50. CINTOSUN U, Altun B, Tasci I
    Sarcopenia Is a Condition With Increasing Importance in Medical Oncology.
    Oncologist. 2016;21:e1.
    PubMed     Text format    


  51. GOSS GD, Spaans JN
    Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
    Oncologist. 2016;21:205-13.
    PubMed     Text format     Abstract available


  52. SEKI Y, Fujiwara Y, Kohno T, Takai E, et al
    Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Oncologist. 2016;21:156-64.
    PubMed     Text format     Abstract available


    January 2016
  53. VERMA V, Simone CB 2nd, Zhen W
    Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer.
    Oncologist. 2016 Jan 13. pii: theoncologist.2015-0348.
    PubMed     Text format    


  54. KUMAR P, Gareen IF, Lathan C, Sicks JD, et al
    Racial Differences in Tobacco Cessation and Treatment Usage After Lung Screening: An Examination of the National Lung Screening Trial.
    Oncologist. 2016;21:40-9.
    PubMed     Text format     Abstract available


    November 2015
  55. NIPP RD, Greer JA, El-Jawahri A, Traeger L, et al
    Age and Gender Moderate the Impact of Early Palliative Care in Metastatic Non-Small Cell Lung Cancer.
    Oncologist. 2015 Nov 30. pii: theoncologist.2015-0232.
    PubMed     Text format     Abstract available


  56. STENEHJEM DD, Bellows BK, Yager KM, Jones J, et al
    Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
    Oncologist. 2015 Nov 27. pii: theoncologist.2015-0162.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: